Literature DB >> 18274339

Foam sclerotherapy of venous malformations.

J Bergan1, V Cheng.   

Abstract

Venous malformations may occur either as localized or segmental lesions. Radiologic imaging defines the extent of involvement but magnetic resonance imaging is the best modality: it gives a bright hypersignal on T2-weighted spin-echo sequences. During a 30-month period, 1427 patients were investigated for venous disorders and 1% were found to have venous angiomata (9 women and 5 men). The age range was 15 to 76 years (mean 30.8+/-18.6 years). Foam was produced by the Tessari technique using 1% or 2% concentration of polidocanol. The duplex Doppler was used for ultrasound guidance to insure intravenous flow of foam and to monitor effects of treatment. A goal of pain-free healing of ulcers or cosmetic improvement was set for each patient. The mean number of treatments was 3.6+/-2.8 (range 1-10). Pain-free healing was achieved in patients with non-healing ulcerations and cosmetically, all of the patients were improved. Sclerosant foam is useful in treating low-flow venous malformations.

Entities:  

Mesh:

Year:  2007        PMID: 18274339     DOI: 10.1258/026835507782655281

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  4 in total

Review 1.  Venous malformation: update on aetiopathogenesis, diagnosis and management.

Authors:  A Dompmartin; M Vikkula; L M Boon
Journal:  Phlebology       Date:  2010-10       Impact factor: 1.740

2.  Lymphatic malformations: current status.

Authors:  Niti Khunger
Journal:  J Cutan Aesthet Surg       Date:  2010-09

3.  Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report.

Authors:  Chihiro Itou; Jun Koizumi; Takeshi Hashimoto; Kazunori Myojin; Tatehiro Kagawa; Tetsuya Mine; Yutaka Imai
Journal:  Cardiovasc Intervent Radiol       Date:  2013-10-30       Impact factor: 2.740

Review 4.  Venous Thromboembolism in Pediatric Vascular Anomalies.

Authors:  Taizo A Nakano; Chadi Zeinati
Journal:  Front Pediatr       Date:  2017-07-24       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.